A. Edward Yen, MD, presented “Clinical Case Discussion: Metastatic Prostate Cancer and Evidence for More Precision Therapy” virtually during the Innovations in Urologic Practice 2020 virtual conference in September 2020.
How to cite: Yen, A. Edward. “Clinical Case Discussion: Metastatic Prostate Cancer and Evidence for More Precision Therapy” September 26th, 2020. Accessed Dec 2024. https://grandroundsinurology.com/clinical-case-discussion-metastatic-prostate-cancer-and-evidence-for-more-precision-therapy/
Summary:
A. Edward Yen, MD, Assistant Professor of Medicine in the Hematology and Oncology Section at Baylor College of Medicine, introduces a metastatic prostate cancer case, and through it explores and reviews treatment options. He discusses homologous recombination and the role that it plays in DNA repair pathways, noting that 25% of patients with advanced prostate cancer have deleterious mutations in DNA damage repair genes which lead to an increased risk of prostate cancer and chance of having nodal and/or distant metastases. Dr. Yen then reviews the TRITON2 study on rucaparib in mCRPC patients with homologous recombination deficiency and the PROfound study on olaparib in mCRPC patients with homologous recombination repair alterations, both of which found a far greater response to treatment in the cohorts with the target mutations. Next, Dr. Yen discusses PARP inhibitors and their side effects, such as fatigue, nausea, pulmonary embolism, anemia, and others. Through his exploration of treatment options, Dr. Yen concludes that next-line chemotherapy is the best option for the patient given the visceral progression of their disease.
About the Innovations in Urologic Practice 2020 virtual conference:
Presented by co-chairs Mohit Khera, MD, MBA, MPH, and Michael Coburn, MD, FACS, the Innovations in Urologic Practice conference provides a detailed review and commentary on multiple genitourinary and urologic diseases. Among the featured oncological topics are bladder cancer and immunotherapies, as well as upper tract cancer management, prostate cancer, including state-of-the-art imaging, focal therapy, and MRI. Experts also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma. In terms of general urological approaches, the conference also includes pelvic reconstruction and trauma, men’s health topics like male infertility and sexual dysfunction, and ways to diagnose and treat infections in the urology patient. Dr. Yen presented this talk virtually at this year’s conference.
ABOUT THE AUTHOR
A. Edward Yen, MD, is an assistant professor of medicine in the hematology and oncology section at Baylor College of Medicine in Houston, Texas. He is a practicing genitourinary medical oncologist at the Dan L Duncan Comprehensive Cancer Center and the Bladder Cancer Center at Baylor He is also affiliated with Baylor St. Luke’s Medical Center and the Houston VA Medical Center Hospital. Dr. Yen earned his MD from Baylor College of Medicine. His research on androgen receptors in hormone-dependent and castration-resistant prostate cancer has been published in Pharmacology & Therapeutics. His professional interests include prostate and genitourinary cancers.
